Literature DB >> 21717447

The enigma of myxofibrosarcoma of the extremity.

Robert W Mutter1, Samuel Singer, Zhigang Zhang, Murray F Brennan, Kaled M Alektiar.   

Abstract

BACKGROUND: The reported high rate of local recurrence (LR) in myxofibrosarcoma raises the question of whether this sarcoma histology should be considered radioresistant. In this study, the authors compared rates and patterns of LR of high-grade (HG) myxofibrosarcoma with rates and patterns of HG leiomyosarcoma, which was chosen because of the similarity in incidence and general treatment approach.
METHODS: Two hundred two patients with primary, nonmetastatic extremity myxofibrosarcoma (n = 114) and leiomyosarcoma (n = 88) underwent limb-sparing surgery and were followed prospectively. All 202 patients had HG tumors, and 138 patients (68%) received adjuvant radiation therapy.
RESULTS: The groups were comparable in terms of age, sex, and receipt of chemotherapy. Compared with leiomyosarcoma, myxofibrosarcoma presented more frequently with tumors >5 cm (P < .001), deep location (P = .036), and upper extremity site (P = .015). In addition, rates of positive/close margins (P < .001) and the receipt of radiation therapy (P < .001) were significantly higher in the myxofibrosarcoma group. The 5-year overall LR rate was not significantly different according to histology (14.6% for myxofibrosarcoma, 13.2% for leiomyosarcoma; P = .594). The only predictor of LR for the whole cohort of patients was positive/close margins (P = .01). Of 17 myxofibrosarcoma LRs, 8 (47%) occurred out of field, versus 1 of 12 (8%) leiomyosarcoma LRs (P = .04). Leiomyosarcoma more commonly recurred distantly (54.1% vs 24.3% at 5 years; P = .014).
CONCLUSIONS: Despite more adverse clinical features, myxofibrosarcoma recurred distantly less often than leiomyosarcoma, whereas the LR rates were comparable between the 2 groups, suggesting that adjuvant radiation therapy is effective in myxofibrosarcoma. Myxofibrosarcoma LRs more commonly occurred out of field. Reduction in radiation field margins may not be advisable in patients with myxofibrosarcoma.
Copyright © 2011 American Cancer Society.

Entities:  

Mesh:

Year:  2011        PMID: 21717447      PMCID: PMC3360945          DOI: 10.1002/cncr.26296

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  34 in total

Review 1.  Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy.

Authors:  B J Longley; M J Reguera; Y Ma
Journal:  Leuk Res       Date:  2001-07       Impact factor: 3.156

2.  Long-term outcome of patients with American Joint Committee on Cancer stage IIB extremity soft tissue sarcomas.

Authors:  J B Fleming; R S Berman; S C Cheng; N P Chen; K K Hunt; B W Feig; P M Respondek; A W Yasko; A Pollack; S R Patel; M A Burgess; N E Papadopoulos; C Plager; G Zagars; R S Benjamin; R E Pollock; P W Pisters
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

3.  Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study.

Authors:  A T van Oosterom; I Judson; J Verweij; S Stroobants; E Donato di Paola; S Dimitrijevic; M Martens; A Webb; R Sciot; M Van Glabbeke; S Silberman; O S Nielsen
Journal:  Lancet       Date:  2001-10-27       Impact factor: 79.321

4.  Extremity soft tissue sarcoma in a series of patients treated at a single institution: local control directly impacts survival.

Authors:  Alessandro Gronchi; Salvatore Lo Vullo; Chiara Colombo; Paola Collini; Silvia Stacchiotti; Luigi Mariani; Marco Fiore; Paolo Giovanni Casali
Journal:  Ann Surg       Date:  2010-03       Impact factor: 12.969

5.  An effective preoperative three-dimensional radiotherapy target volume for extremity soft tissue sarcoma and the effect of margin width on local control.

Authors:  BoKyong Kim; Yen-Lin E Chen; David G Kirsch; Saveli I Goldberg; Wendy Kobayashi; Jong Hyun Kung; John A Wolfgang; Karen Doppke; Andrew E Rosenberg; G Petur Nielsen; Kevin A Raskin; Dempsey S Springfield; Joseph H Schwab; Mark C Gebhardt; Sam S Yoon; Francis J Hornicek; Thomas F DeLaney
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-12-16       Impact factor: 7.038

6.  Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy.

Authors:  Jordi Barretina; Barry S Taylor; Shantanu Banerji; Alexis H Ramos; Mariana Lagos-Quintana; Penelope L Decarolis; Kinjal Shah; Nicholas D Socci; Barbara A Weir; Alan Ho; Derek Y Chiang; Boris Reva; Craig H Mermel; Gad Getz; Yevgenyi Antipin; Rameen Beroukhim; John E Major; Charles Hatton; Richard Nicoletti; Megan Hanna; Ted Sharpe; Tim J Fennell; Kristian Cibulskis; Robert C Onofrio; Tsuyoshi Saito; Neerav Shukla; Christopher Lau; Sven Nelander; Serena J Silver; Carrie Sougnez; Agnes Viale; Wendy Winckler; Robert G Maki; Levi A Garraway; Alex Lash; Heidi Greulich; David E Root; William R Sellers; Gary K Schwartz; Cristina R Antonescu; Eric S Lander; Harold E Varmus; Marc Ladanyi; Chris Sander; Matthew Meyerson; Samuel Singer
Journal:  Nat Genet       Date:  2010-07-04       Impact factor: 38.330

7.  Preliminary results from a prospective study using limited margin radiotherapy in pediatric and young adult patients with high-grade nonrhabdomyosarcoma soft-tissue sarcoma.

Authors:  Matthew J Krasin; Andrew M Davidoff; Xiaoping Xiong; Shengjie Wu; Chia-Ho Hua; Fariba Navid; Carlos Rodriguez-Galindo; Bhaskar N Rao; Kelly A Hoth; Michael D Neel; Thomas E Merchant; Larry E Kun; Sheri L Spunt
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-07-20       Impact factor: 7.038

8.  Excellent local control rates and distinctive patterns of failure in myxoid liposarcoma treated with conservation surgery and radiotherapy.

Authors:  B Ashleigh Guadagnolo; Gunar K Zagars; Matthew T Ballo; Shreyaskumar R Patel; Valerae O Lewis; Robert S Benjamin; Raphael E Pollock
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-09-24       Impact factor: 7.038

9.  Radiosensitivity translates into excellent local control in extremity myxoid liposarcoma: a comparison with other soft tissue sarcomas.

Authors:  Peter W M Chung; Benjamin M Deheshi; Peter C Ferguson; Jay S Wunder; Anthony M Griffin; Charles N Catton; Robert S Bell; Lawrence M White; Rita A Kandel; Brian O'Sullivan
Journal:  Cancer       Date:  2009-07-15       Impact factor: 6.860

10.  Intensity modulated radiation therapy for primary soft tissue sarcoma of the extremity: preliminary results.

Authors:  Kaled M Alektiar; Linda Hong; Murray F Brennan; Cesar Della-Biancia; Samuel Singer
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-03-23       Impact factor: 7.038

View more
  15 in total

1.  Myxofibrosarcoma with metastasis to the lungs, pleura, and mediastinum: a case report and review of literature.

Authors:  Catherine Hambleton; Salem Noureldine; Farrukh Gill; Krzysztof Moroz; Emad Kandil
Journal:  Int J Clin Exp Med       Date:  2012-01-15

2.  Local Recurrence of Soft Tissue Sarcoma Revisited: Is there a Role for "Selective" Radiation?

Authors:  Nathan E Saxby; Qiang An; Benjamin J Miller
Journal:  Iowa Orthop J       Date:  2022-06

3.  Synovial sarcoma of the elbow presenting with painful stiffness: a case report.

Authors:  Jennifer L Nevin; Graham Jw King
Journal:  Shoulder Elbow       Date:  2020-11-26

4.  Prognostic Impact of CD44 Expression in Patients With Myxofibrosarcoma.

Authors:  Hiroyuki Tsuchie; Makoto Emori; Naohisa Miyakoshi; Hiroyuki Nagasawa; Kyoji Okada; Hiroshi Nanjyo; Yasutaka Murahashi; Emi Mizushima; Junya Shimizu; Toshihiko Yamashita; Yoichi Shimada
Journal:  In Vivo       Date:  2019 Nov-Dec       Impact factor: 2.155

5.  Prognostic significance of histological invasion in high grade soft tissue sarcomas.

Authors:  Satoshi Tsukushi; Yoshihiro Nishida; Hiroshi Urakawa; Eiji Kozawa; Naoki Ishiguro
Journal:  Springerplus       Date:  2014-09-22

6.  Low-Grade Myxofibrosarcoma of the Rectus Abdominus Muscle Infiltrating into Abdominal Cavity: A Case Report.

Authors:  Tadashi Nomura; Shunsuke Sakakibara; Aya Moriwaki; Teruya Kawamoto; Satoshi Suzuki; Takeshi Ishimura; Kazunobu Hashikawa; Hiroto Terashi
Journal:  Eplasty       Date:  2017-02-21

7.  Distant metastasis in patients with myxofibrosarcoma.

Authors:  Hiroyuki Tsuchie; Mitsunori Kaya; Hiroyuki Nagasawa; Makoto Emori; Yasutaka Murahashi; Emi Mizushima; Naohisa Miyakoshi; Toshihiko Yamashita; Yoichi Shimada
Journal:  Ups J Med Sci       Date:  2017-08-17       Impact factor: 2.384

Review 8.  Multiple recurrent myxofibrosarcoma of the orbit: case report and review of the literature.

Authors:  Baixue Du; Xin He; Yujiao Wang; Weimin He
Journal:  BMC Ophthalmol       Date:  2020-07-06       Impact factor: 2.209

9.  MET-overexpressing myxofibrosarcoma frequently exhibit polysomy of chromosome 7 but not MET amplification, especially in high-grade cases: clinical and pathological review of 30 myxofibrosarcoma cases.

Authors:  Shirong Ma; Linni Fan; Yixiong Liu; Yingmei Wang; Kangjie Yu; Lifeng Wang; Na Fang; Fang Liu; Shuangping Guo; Zhe Wang
Journal:  Diagn Pathol       Date:  2018-08-21       Impact factor: 2.644

10.  Myxofibrosarcoma with associated Mycobacterium infection.

Authors:  Sean Chen; Peter Mattei; Jens U Berli; Jaimie Shores
Journal:  Eplasty       Date:  2014-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.